SCHEMBL2450409

SCHEMBL2450409

NCc1cccc(-c2ccccc2O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
HPGD P15428 1/20 0.52
BCL2L1 Q07817 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ENPP2 Q13822 1/20 0.52
PTPN5 P54829 1/20 0.47
HTR7 P34969 1/20 0.47
LOXL2 Q9Y4K0 2/20 0.46
TAAR1 Q96RJ0 1/20 0.45
BACE1 P56817 1/20 0.45
ESR2 Q92731 1/20 0.44
CFD P00746 3/20 0.44
KISS1R Q969F8 1/20 0.44
CSNK2A1 P68400 2/20 0.43
PNMT P11086 1/20 0.42
FGFR1 P11362 1/20 0.40
FGFR2 P21802 1/20 0.40
FGFR3 P22607 1/20 0.40
PLG P00747 1/20 0.40
PLAU P00749 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28241992 0.93 ENPP2 (0.48) ALDH1A1HPGDBCL2L1HSD17B10ENPP2
SCHEMBL20994110 0.83 ALDH1A1 (0.59) ALDH1A1HPGDBCL2L1HSD17B10ENPP2
SCHEMBL28241993 0.83 CSNK2A1 (0.46) ALDH1A1HPGDBCL2L1HSD17B10ENPP2
SCHEMBL2564396 0.82 ALDH1A1 (0.58) ALDH1A1HPGDBCL2L1HSD17B10ENPP2
SCHEMBL27649924 0.82 LOXL2 (0.58) ALDH1A1HSD17B10ENPP2HTR7LOXL2
SCHEMBL5685024 0.82 ENPP2 (0.48) ENPP2HTR7LOXL2TAAR1BACE1
SCHEMBL28055811 0.82 ENPP2 (0.58) ENPP2LOXL2TAAR1BACE1ESR2
SCHEMBL28241991 0.82 ENPP2 (0.53) BCL2L1ENPP2HTR7LOXL2TAAR1
SCHEMBL21257503 0.81 ALDH1A1 (0.52) ALDH1A1HPGDBCL2L1HSD17B10PTPN5
SCHEMBL27652255 0.81 ALDH1A1 (0.52) ALDH1A1HPGDBCL2L1HSD17B10PTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108884040-A Novel dihydroxy compounds 本州化学工业株式会社 2018-11-23 CN disclosed
WO-2016060516-A1 A PLURALITY OF HOST MATERIALS AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE SAME ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) 2016-04-21 WO disclosed
US-8013019-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC (US) 2011-09-06 US disclosed
US-8013019-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC (US) 2011-09-06 US disclosed
US-8013019-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC (US) 2011-09-06 US disclosed
US-20100273758-A1 Sulfonamide Derivatives For The Treatment Of Diseases BROWN ALAN DANIEL 2010-10-28 US disclosed
US-20100273758-A1 Sulfonamide Derivatives For The Treatment Of Diseases BROWN ALAN DANIEL 2010-10-28 US disclosed
US-20100273758-A1 Sulfonamide Derivatives For The Treatment Of Diseases BROWN ALAN DANIEL 2010-10-28 US disclosed
US-7767715-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC (US) 2010-08-03 US disclosed
US-7767715-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC (US) 2010-08-03 US disclosed
US-7528170-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC. (US) 2009-05-05 US disclosed
US-7528170-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC. (US) 2009-05-05 US disclosed
US-20080267970-A1 Sulfonamide Derivatives For The Treatment of Diseases BROWN ALAN DANIEL 2008-10-30 US disclosed
US-20080267970-A1 Sulfonamide Derivatives For The Treatment of Diseases BROWN ALAN DANIEL 2008-10-30 US disclosed
US-20080267970-A1 Sulfonamide Derivatives For The Treatment of Diseases BROWN ALAN DANIEL 2008-10-30 US disclosed
EP-1708991-B1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES PFIZER LTD (GB) 2007-10-17 EP disclosed
US-7244766-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC (US) 2007-07-17 US disclosed
US-7244766-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC (US) 2007-07-17 US disclosed
US-7244766-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC (US) 2007-07-17 US disclosed
US-20050182091-A1 For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal PFIZER INC. 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273758-A1 Sulfonamide Derivatives For The Treatment Of Diseases SULT2A1, STS, SULT1A1 ALDH1A1 178/4885HPGD 284/4885BCL2L1 3918/4885
US-20050182091-A1 For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal LTC4S, LTB4R2, LTB4R ALDH1A1 130/4885HPGD 20/4885BCL2L1 3950/4885
US-20080267970-A1 Sulfonamide Derivatives For The Treatment of Diseases SULT2A1, STS, SULT1A1 ALDH1A1 178/4885HPGD 284/4885BCL2L1 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.